Results 201 to 210 of about 45,666 (299)

Biomimetic 3D‐Printed Adaptive Hydrogel Bioadhesives Featuring Superior Infection Resistance for Challenging Tissue Adhesion, Hemostasis, and Healthcare

open access: yesAdvanced Materials, EarlyView.
Biomimetic 3D‐printed hydrogel bioadhesives (PTLAs) are designed to address the limitations of existing bioadhesives, offering solutions for challenging tissue adhesion and enhanced healthcare. These PTLAs feature robust wet/underwater tissue adhesion/sealing, superior freeze/pressure and infection resistance, and adaptive self‐healing/gelling capacity,
Qi Wu   +4 more
wiley   +1 more source

Bioprinted Constructs in the Regulatory Landscape: Current State and Future Perspectives

open access: yesAdvanced Materials, EarlyView.
Bioprinting has rapidly emerged as a transformative technology in biomedical research, offering unprecedented potential to replicate complex tissues. Despite its promise, clinical translation remains limited due to regulatory hurdles. This review explores global regulatory frameworks, comparing approaches in the EU, U.S., China, and Australia, and ...
Francesca Perin   +6 more
wiley   +1 more source

Harnessing clonal diversity in grapevine: from genomic insights to modern breeding applications. [PDF]

open access: yesTheor Appl Genet
Callipo P   +5 more
europepmc   +1 more source

Volumetric 3D Printing and Melt‐Electrowriting to Fabricate Implantable Reinforced Cardiac Tissue Patches

open access: yesAdvanced Materials, EarlyView.
This study presents an implantable reinforced cardiac patch (RCPatch) combining volumetrically 3D‐printed metamaterials with melt‐electrowritten (MEW) meshes. The design integrates tunable stiff polymer structures with soft, cell‐laden hydrogels. The RCPatch withstands suturing, intraventricular pressure, and cardiac contraction in a large animal ...
Lewis S. Jones   +12 more
wiley   +1 more source

MUTE‐Seq: An Ultrasensitive Method for Detecting Low‐Frequency Mutations in cfDNA With Engineered Advanced‐Fidelity FnCas9

open access: yesAdvanced Materials, EarlyView.
An advanced‐fidelity CRISPR nuclease, FnCas9‐AF2, is rationally engineered to discriminate single‐base mismatches with unprecedented level precision. Integrated into the MUTE‐Seq workflow, FnCas9‐AF2 depletes wild‐type cell‐free DNA, thereby exposing rare tumor‐derived mutant DNA (a molecular “needle in a haystack”).
Sunghyeok Ye   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy